|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
44,500,000 |
Market
Cap: |
224.73(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.78 - $10.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE silencing technology.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,447 |
29,851 |
83,116 |
204,188 |
Total Sell Value |
$6,309 |
$149,864 |
$489,708 |
$2,829,450 |
Total People Sold |
1 |
12 |
13 |
15 |
Total Sell Transactions |
1 |
12 |
15 |
48 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gut Robert |
Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$26,753 |
D/D |
(1,602) |
35,085 |
|
- |
|
Springhorn Jeremy P. |
Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
10,877 |
|
- |
|
Kaye Jack |
Director |
|
2022-02-28 |
4 |
S |
$16.76 |
$10,056 |
D/D |
(600) |
19,003 |
|
- |
|
Dolmetsch Ricardo |
President, R&D |
|
2022-02-28 |
4 |
S |
$16.68 |
$24,753 |
D/D |
(1,484) |
122,325 |
|
- |
|
Meek David D. |
Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
7,380 |
|
- |
|
Klemt Christian |
Chief Financial Officer |
|
2022-02-28 |
4 |
S |
$16.80 |
$68,460 |
D/D |
(4,075) |
106,375 |
|
- |
|
Soteropoulos Paula |
Director |
|
2022-02-28 |
4 |
S |
$16.87 |
$10,055 |
D/D |
(596) |
7,302 |
|
- |
|
Balachandran Madhavan |
Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
10,877 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2022-02-28 |
4 |
S |
$16.72 |
$56,932 |
D/D |
(3,405) |
95,156 |
|
- |
|
Kapusta Matthew C |
CEO & Managing Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$170,257 |
D/D |
(10,195) |
360,554 |
|
- |
|
Post Leonard E |
Director |
|
2022-02-28 |
4 |
S |
$16.64 |
$13,229 |
D/D |
(795) |
3,121 |
|
- |
|
Jacques Rachelle Suzanne |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
1,534 |
|
- |
|
Gut Robert |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
36,687 |
|
- |
|
Soteropoulos Paula |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
7,898 |
|
- |
|
Dolmetsch Ricardo |
President, R&D |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
54,683 |
123,809 |
|
- |
|
Kaye Jack |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
19,603 |
|
- |
|
Springhorn Jeremy P. |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
11,479 |
|
- |
|
Post Leonard E |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
3,916 |
|
- |
|
Meek David D. |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
7,982 |
|
- |
|
Caloz Pierre |
Chief Operating Officer |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
37,086 |
72,086 |
|
- |
|
Balachandran Madhavan |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
11,479 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,904 |
98,601 |
|
- |
|
Kapusta Matthew C |
CEO and Managing Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
125,073 |
370,749 |
|
- |
|
Klemt Christian |
Chief Financial Officer |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,630 |
110,450 |
|
- |
|
Gut Robert |
Director |
|
2022-01-26 |
4 |
S |
$18.12 |
$42,546 |
D/D |
(2,348) |
35,153 |
|
- |
|
336 Records found
|
|
Page 4 of 14 |
|
|